Alexander disease

Alexander disease is a rare disorder of the nervous system. It is one of a group of disorders, called leukodystrophies, that involve the destruction of myelin. Myelin is the fatty covering that insulates nerve fibers and promotes the rapid transmission of nerve impulses. If myelin is not properly maintained, the transmission of nerve impulses could be disrupted. As myelin deteriorates in leukodystrophies such as Alexander disease, nervous system functions are impaired.

Most cases of Alexander disease begin before age 2 and are described as the infantile form. Signs and symptoms of the infantile form typically include an enlarged brain and head size (megalencephaly), seizures, stiffness in the arms and/or legs (spasticity), intellectual disability, and developmental delay. Less frequently, onset occurs later in childhood (the juvenile form) or in adulthood. Common problems in juvenile and adult forms of Alexander disease include speech abnormalities, swallowing difficulties, seizures, and poor coordination (ataxia). Rarely, a neonatal form of Alexander disease occurs within the first month of life and is associated with severe intellectual disability and developmental delay, a buildup of fluid in the brain (hydrocephalus), and seizures.

Alexander disease is also characterized by abnormal protein deposits known as Rosenthal fibers. These deposits are found in specialized cells called astroglial cells, which support and nourish other cells in the brain and spinal cord (central nervous system).

Frequency

The prevalence of Alexander disease is unknown. About 500 cases have been reported since the disorder was first described in 1949.

Genetic Changes

Mutations in the GFAP gene cause Alexander disease. The GFAP gene provides instructions for making a protein called glial fibrillary acidic protein. Several molecules of this protein bind together to form intermediate filaments, which provide support and strength to cells. Mutations in the GFAP gene lead to the production of a structurally altered glial fibrillary acidic protein. The altered protein is thought to impair the formation of normal intermediate filaments. As a result, the abnormal glial fibrillary acidic protein likely accumulates in astroglial cells, leading to the formation of Rosenthal fibers, which impair cell function. It is not well understood how impaired astroglial cells contribute to the abnormal formation or maintenance of myelin, leading to the signs and symptoms of Alexander disease.
Inheritance Pattern

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

Most cases result from new mutations in the gene. These cases occur in people with no history of the disorder in their family. Rarely, an affected person inherits the mutation from one affected parent.

Other Names for This Condition

- Alexander's disease
- ALX
- AxD
- demyelinogenic leukodystrophy
- dysmyelinogenic leukodystrophy
- fibrinoid degeneration of astrocytes
- leukodystrophy with Rosenthal fibers

Diagnosis & Management

Genetic Testing

- Genetic Testing Registry: Alexander's disease

Other Diagnosis and Management Resources

- GeneReview: Alexander Disease
  https://www.ncbi.nlm.nih.gov/books/NBK1172
- MedlinePlus Encyclopedia: Myelin
  https://medlineplus.gov/ency/article/002261.htm

General Information from MedlinePlus

- Diagnostic Tests
  https://medlineplus.gov/diagnostictests.html
- Drug Therapy
  https://medlineplus.gov/drugtherapy.html
- Genetic Counseling
  https://medlineplus.gov/geneticcounseling.html
• Palliative Care  
  https://medlineplus.gov/palliativecare.html  
• Surgery and Rehabilitation  
  https://medlineplus.gov/surgeryandrehabilitation.html

**Additional Information & Resources**

**MedlinePlus**

• Encyclopedia: Myelin  
  https://medlineplus.gov/ency/article/002261.htm
• Health Topic: Degenerative Nerve Diseases  
  https://medlineplus.gov/degenerativenervediseases.html
• Health Topic: Leukodystrophies  
  https://medlineplus.gov/leukodystrophies.html

**Genetic and Rare Diseases Information Center**

• Alexander disease  
  https://rarediseases.info.nih.gov/diseases/5774/alexander-disease

**Additional NIH Resources**

• National Institute of Neurological Disorders and Stroke: Alexander Disease  
  https://www.ninds.nih.gov/Disorders/All-Disorders/Alexander-disease-Information-Page
• National Institute of Neurological Disorders and Stroke: Leukodystrophy  
  https://www.ninds.nih.gov/Disorders/All-Disorders/Leukodystrophy-Information-Page
• National Institutes of Neurological Disorders and Stroke: Megalencephaly  
  https://www.ninds.nih.gov/Disorders/All-Disorders/Megalencephaly-Information-Page

**Educational Resources**

• Disease InfoSearch: Alexander Disease  
  http://www.diseaseinfosearch.org/Alexander+Disease/302
• Kennedy Krieger Institute: Neurodegenerative Disorders  
  https://www.kennedykrieger.org/patient-care/diagnoses-disorders/neurodegenerative-disorders
• MalaCards: alexander disease  
  http://www.malacards.org/card/alexander_disease
• Orphanet: Alexander disease
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=58

• Waisman Center
  https://www.waisman.wisc.edu/stem-cell-research-program/alexander-disease/

**Patient Support and Advocacy Resources**

• National Organization for Rare Diseases (NORD)
  https://rarediseases.org/rare-diseases/alexander-disease/

• United Leukodystrophy Foundation
  http://ulf.org/alexander-disease/

• University of Kansas Medical Center
  http://www.kumc.edu/gec/support/leukodys.html

**GeneReviews**

• Alexander Disease
  https://www.ncbi.nlm.nih.gov/books/NBK1172

**ClinicalTrials.gov**

• ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22alexander+disease%22

**Scientific Articles on PubMed**

• PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Alexander+disease%5BTiab %5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last +1080+days%22%5Bdp%5D

**OMIM**

• ALEXANDER DISEASE
  http://omim.org/entry/203450

**Sources for This Summary**

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16807904

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24306001
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873623/
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15732097

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17498694 
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702672/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301351

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23364391

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16505300


Reviewed: October 2015
Published: July 17, 2018

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services